Gadi Saarony - PAREXEL International Senior Vice President - Clinical Research Services

PRXL -- USA Stock  

null 88.06  0.04  0.0454%

  President
Mr. Gadi Saarony is Senior Vice President Clinical Research of Parexel International Corporationrationration. In this position, Mr. Saarony is responsible for global project leadership and for clinical operations for our CRS business unit. From January 2008 to July 2012, Mr. Saarony was Corporationrationrate Vice President and World Wide Head, PAREXEL Consulting and Medical Communications . From July 2007 to January 2008, he served as Corporationrationrate Vice President and General Manager, PAREXEL Consulting. Prior to this, Mr. Saarony held various positions of increasing responsibility with the Company. Prior to joining the Company in 2003, Mr. Saarony was Director of Consulting Services for Habama, Inc. and Associate Director, Strategy, with Ernst Young, LLP, Inc. He graduated from Rider University with a degree in Economics and holds a masters degree in International Business from The American Graduate School of International Business .
Age: 47  President Since 2012      
781 487-9900  http://www.parexel.com

Management Efficiency

The company has return on total asset (ROA) of 6.72 % which means that it generated profit of $6.72 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 16.93 % meaning that it created $16.93 on every $100 dollars invested by stockholders.
The company currently holds 671.5M in liabilities with Debt to Equity (D/E) ratio of 105.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has Current Ratio of 1.42 which is within standard range for the sector.

Similar Executives

Showing few of many executives

PRESIDENT Since

Amit BiswasDr Reddys Laboratories Ltd
2016
Grainne QuinnPerrigo Company plc
2016
Joseph LaRosaRegeneron Pharmaceuticals
2019
Marc CouckePerrigo Company plc
N/A
Umang VohraDr Reddys Laboratories Ltd
2013
Alejandro BernalZoetis
2015
Louis YuPerrigo Company plc
2013
Charles MilsteinVertex Pharmaceuticals Incorpor
2017
Scott JamisonPerrigo Company plc
2011
Michael PariniVertex Pharmaceuticals Incorpor
2017
Marion McCourtRegeneron Pharmaceuticals
2018
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
2014
Qiang GaoSinovac Biotech Ltd
2016
Paul WeningerPerrigo Company plc
2015
Michael AbermanRegeneron Pharmaceuticals
2015
Michael PartridgeVertex Pharmaceuticals Incorpor
N/A
John WesolowskiPerrigo Company plc
2016
Sripada ChandrasekharDr Reddys Laboratories Ltd
2013
Sandra BeatyZoetis
2012
Roxanne LaganoZoetis
2015
Reshma KewalramaniVertex Pharmaceuticals Incorpor
2018

Entity Summary

PAREXEL International Corporationration, a biopharmaceutical services company, offer clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology solutions and services for pharmaceutical, biotechnology, and medical device industries worldwide. PAREXEL International Corp (PRXL) is traded on NASDAQ in USA and employs 18,600 people.

PAREXEL International Leadership Team

Michelle Graham, Chief Human Resource Officer, Senior Vice President
Ulf Schneider, Chief Administrative Officer, Senior Vice President
Thomas Senderovitz, Senior Vice President - Clinical Research Services
Dana Callow, Presiding Independent Director
Emma Reeve, Interim CFO, Corporate Vice President Controller
Josef Rickenbach, Founder, Chairman and CEO
Patrick Fortune, Independent Director
Eduard Holdener, Independent Director
Simon Harford, CFO, Senior Vice President
Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access
Gadi Saarony, Senior Vice President - Clinical Research Services
Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center
Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting
Xavier Flinois, President - Perceptive Informatics
Douglas Batt, Sr. VP, General Counsel and Secretary
Sybrand Pretorius, Senior Vice President Chief Scientific Officer
Maykin Ho, Director
Richard Love, Independent Director
Ronald Aldridge, Sr. Director, Investor Relations
Mark Goldberg, President COO
Roland Andersson, Senior Vice President - Clinical Research Services
Christopher Lindop, Independent Director
Ingo Bank, CFO and Sr. VP
David Godwin, Senior Vice President-Global Business

Stock Performance Indicators

Current Sentiment - PRXL

PAREXEL International Investor Sentiment

Most of Macroaxis users are at this time bullish on PAREXEL International Corp. What is your perspective on investing in PAREXEL International Corp? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Currently Active Assets on Macroaxis

TWTR   
Purchased over 50 shares of
few hours ago
Traded for 1.0
MGTI   
Purchased over 50 shares of
few hours ago
Traded for 1.0
PVCT   
Purchased over 10K shares of
few hours ago
Traded for 1.0
BTSC   
Purchased over 10K shares of
few hours ago
Traded for 1.0
ALNY   
Purchased few shares of
few hours ago
Traded for 1.0
Additionally take a look at Your Equity Center. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.
Search macroaxis.com